PMHNP-led hormone therapy for perimenopausal depression, PMDD, postpartum mood, and low-T depression. Because the right treatment isn't always another SSRI.
"Hormonal mood disorders are frequently dismissed or over-medicated with antidepressants that don't address the root cause. We look upstream — at estrogen, progesterone, testosterone, and cortisol — before reaching for another SSRI."
— Kristin McKnight, MSN, APRN, PMHNP-BC
These are psychiatric presentations with a hormonal driver — not cosmetic concerns. Each diagnosis is evaluated as part of a complete psychiatric picture.
Irritability, depression, anxiety, and emotional dysregulation during the menopausal transition — often beginning years before the last period. Fluctuating estrogen is a primary driver, not simply "stress."
Severe mood changes, irritability, depression, or anxiety in the week before menstruation that resolve with the onset of flow. A hormonal trigger with psychiatric severity — often responds to hormonal intervention alongside or instead of SSRIs.
Postpartum depression and anxiety with a clear hormonal precipitant — the dramatic drop in estrogen and progesterone after delivery. Hormonal stabilization can be a critical piece of the treatment plan alongside antidepressants.
Abrupt estrogen loss following oophorectomy produces immediate, often severe mood symptoms that differ from natural menopause. Requires prompt hormonal evaluation — not just antidepressant escalation.
Cognitive slowing, memory complaints, and flat affect during menopause — a cluster that responds to estrogen restoration in ways antidepressants alone do not address.
Hot flashes and night sweats that chronically disrupt sleep — which then drives depression, anxiety, and cognitive impairment. Treating the vasomotor root directly often does more for mood than adding a sedative-hypnotic.
Fatigue, low libido, irritability, anhedonia, and flat affect in men (and women) with documented low testosterone — a clinical picture that mimics MDD but responds poorly to antidepressants without addressing the hormonal substrate.
Chronic opioid use suppresses the HPG axis, causing testosterone deficiency in both men and women. A commonly missed contributor to depression, fatigue, and anhedonia in patients on opioid therapy — including those in MAT programs.
Our hormonal psychiatry program has specific clinical boundaries. If you fall into any of these categories, we'll help identify the right referral path.